CIC
ARKG icon

Carnegie Investment Counsel’s ARK Genomic Revolution ETF ARKG Stock Holding History

Carnegie Investment Counsel’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,190
Closed -$200K – 484
2023
Q3 		$200K Sell
7,190
-175
-2% -$5.72K 0.01% 473
2023
Q2 		$251K Sell
7,365
-190
-3% -$5.97K 0.01% 450
2023
Q1 		$227K Sell
7,555
-2,179
-22% -$67.5K 0.01% 473
2022
Q4 		$275K Sell
9,734
-205
-2% -$6.51K 0.01% 437
2022
Q3 		$327K Sell
9,939
-100
-1% -$3.67K 0.02% 392
2022
Q2 		$316K Sell
10,039
-1,209
-11% -$42.3K 0.01% 395
2022
Q1 		$517K Sell
11,248
-850
-7% -$40.5K 0.02% 343
2021
Q4 		$741K Sell
12,098
-11,624
-49% -$804K 0.02% 312
2021
Q3 		$1.77M Buy
23,722
+5,074
+27% +$426K 0.07% 194
2021
Q2 		$1.73M Buy
18,648
+2,727
+17% +$232K 0.07% 201
2021
Q1 		$1.41M Buy
15,921
+12,561
+374% +$1.25M 0.06% 213
2020
Q4 		$313K Buy
+3,360
New +$268K 0.01% 354

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
MM
Main Management San Francisco, California $1.37B AUM 19.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Carnegie Investment Counsel's ARKG Position: Q4 2023 in Review

Carnegie Investment Counsel sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2023, closing a stake of 7,190 shares — an estimated $200K sold.

Carnegie Investment Counsel first reported a position in ARKG in Q4 2020 and held it in 12 quarters. The position peaked at $1.77M in Q3 2021. 298 funds tracked by Wall St. Rank hold ARKG as of Q4 2023.

  • Carnegie Investment Counsel reported no remaining ARK Genomic Revolution ETF position as of Q4 2023 after selling out during the quarter.
  • Carnegie Investment Counsel sold 7,190 ARK Genomic Revolution ETF shares in Q4 2023, an estimated $200K.
  • Carnegie Investment Counsel first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 12 quarters.
  • Carnegie Investment Counsel's ARK Genomic Revolution ETF position peaked at $1.77M in Q3 2021.
  • 298 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2023.

Based on Carnegie Investment Counsel's 13F filing for Q4 2023, filed 30 Jan 2024.